<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9E6E29A1-FFE3-487C-84F6-02CD1B6E313A"><gtr:id>9E6E29A1-FFE3-487C-84F6-02CD1B6E313A</gtr:id><gtr:name>National Institute for Biological Standards and Control (NIBSC)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9C10D78F-6430-4CA7-9528-B96B0762A4C6"><gtr:id>9C10D78F-6430-4CA7-9528-B96B0762A4C6</gtr:id><gtr:name>Cardiff University</gtr:name><gtr:address><gtr:line1>Research &amp; Consultancy</gtr:line1><gtr:line2>PO Box 923</gtr:line2><gtr:line4>Cardiff</gtr:line4><gtr:line5>South Glamorgan</gtr:line5><gtr:postCode>CF10 3TE</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:department>Royal (Dick) School of Veterinary Scienc</gtr:department><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/798CB33D-C79E-4578-83F2-72606407192C"><gtr:id>798CB33D-C79E-4578-83F2-72606407192C</gtr:id><gtr:name>EPSRC</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:line4>Swindon</gtr:line4><gtr:line5>Wiltshire</gtr:line5><gtr:postCode>SN2 1ET</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>CO_FUNDER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9E6E29A1-FFE3-487C-84F6-02CD1B6E313A"><gtr:id>9E6E29A1-FFE3-487C-84F6-02CD1B6E313A</gtr:id><gtr:name>National Institute for Biological Standards and Control (NIBSC)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9C10D78F-6430-4CA7-9528-B96B0762A4C6"><gtr:id>9C10D78F-6430-4CA7-9528-B96B0762A4C6</gtr:id><gtr:name>Cardiff University</gtr:name><gtr:address><gtr:line1>Research &amp; Consultancy</gtr:line1><gtr:line2>PO Box 923</gtr:line2><gtr:line4>Cardiff</gtr:line4><gtr:line5>South Glamorgan</gtr:line5><gtr:postCode>CF10 3TE</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/BE61785F-29B3-4563-B4B3-899E9A07649F"><gtr:id>BE61785F-29B3-4563-B4B3-899E9A07649F</gtr:id><gtr:firstName>Marc Leighton</gtr:firstName><gtr:surname>Turner</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/F0DB2639-B4AC-4B07-B9E6-F4C1111D9BC8"><gtr:id>F0DB2639-B4AC-4B07-B9E6-F4C1111D9BC8</gtr:id><gtr:firstName>Paul</gtr:firstName><gtr:otherNames>Alexandre</gtr:otherNames><gtr:surname>De Sousa</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=BB%2FG010323%2F1"><gtr:id>B1E15C00-569E-40AA-83C9-09211C95B532</gtr:id><gtr:title>A novel characterisation and separation technique for pluripotent human embryonic and hematopoeitic stem cells</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>BB/G010323/1</gtr:grantReference><gtr:abstractText>Realising the promised benefits of stem cells and their derivatives in regenerative medical therapies or in high throughput screening platforms for drug development necessitates the development of tools to purify cells to homogeneity. Ideally, such tools should be non-invasive with a capacity for separation several orders of magnitude beyond current methods. Industrial systems for the purification of therapeutic proteins provide precedents for large scale bioprocessing. To date, the vast majority of these have focused on column chromatography to achieve desired levels of purity. However, the size, sensitivity and complexity of cells present particular challenges to the downstream engineer which are unlikely to be solved by any further evolution or modification of traditional column chromatographic techniques. Consequently, novel techniques are needed. This proposal intends to develop a novel, simple, scalable and commercially useful technique for the separation/purification of human stem cells irrespective of their tissue of origin. This will be achieved by using Atomic Force Microscopy to define the topography and electrical charge distribution on the surfaces of human embryonic and adult haematopoietic stem cells followed by the use of this information in computational models to design complimentary surfaces. Surface prototypes will then be used in small-scale experimental work with living cells to demonstrate their ability to reversibly bind and separate cells and their subsequent viability. By focusing on both charge and topography of stem cell-surfaces the project will produce an adsorption-based separation technology more specifically suited for cell purification than current chromatographic techniques. The use of both adult and embryonic stem cell populations will exemplify the utility of this technology to both current and future clinical and research applications.</gtr:abstractText><gtr:technicalSummary>This proposal intends to develop a scalable separation/purification technique for human stem cells capable of non-invasive and reversible processing of cells that will supercede current methods based on flow cytometry, centrifugation or magnetic separation. By using Atomic Force Microscopy with charged tips to generate charge maps the research will identify surface electrical charge differences associated with specific human stem cell populations, namely embryonic and adult haematopoietic (CD34+) stem cells. This information will be used to computationally model complimentary interactive substrates providing reversible affinity. Small-scale experimental work will be used to evaluate substrate prototypes for their capacity to enrich for stem cell populations without altering their viability or pluripotency, assessed using a range of standardised in vitro assays for cell molecular marker expression, and differentiation potential. By focusing on both charge and topography of surfaces the work will produce an adsorption-based separation technology more specifically suited for cell purification than current chromatographic techniques. This novel technology should be scalable to processing larger quantities of cells (10 E9-10) than current methods, thus making it a commercially useful solid-phase separation technique.</gtr:technicalSummary><gtr:fund><gtr:end>2012-06-10</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/2512EF1C-401B-4222-9869-A770D4C5FAC7"><gtr:id>2512EF1C-401B-4222-9869-A770D4C5FAC7</gtr:id><gtr:name>BBSRC</gtr:name></gtr:funder><gtr:start>2009-06-11</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>105412</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Institute for Biological Standards and Control (NIBSC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>EBiSC</gtr:description><gtr:id>0F609906-62A7-44AB-A20D-21CEF36F3A69</gtr:id><gtr:impact>EC/IMI funded European Bank for Induced Stem Cells. I lead workpackage establishing foundational collection whilst collaborator leads on quality control WP.</gtr:impact><gtr:outcomeId>57bb1456e043f8.39494046-1</gtr:outcomeId><gtr:partnerContribution>Consensus standards for human pluripotent stem cell production and quality control</gtr:partnerContribution><gtr:piContribution>Consensus standards for human pluripotent stem cell production and quality control</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cardiff University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Brain repair group</gtr:department><gtr:description>RepairHD</gtr:description><gtr:id>754F5B3C-4466-4FD9-BA7C-E023C6BCA67D</gtr:id><gtr:impact>The principle outcome constitutes an EUFP7 funded RepairHD programme which focuses on Good Manufaturing Practice grade translation and preclinical animal model verification of bioactivity of an hESC derived cell therapy product in animal models of Huntingtons Disease. My expertise in GMP, hESC biosafety and supportive technology arising from MRC, CSO and BBSRC awards, awards contributes to this collaboration/partnership.</gtr:impact><gtr:outcomeId>57bb187e99fcd8.02353604-1</gtr:outcomeId><gtr:partnerContribution>Neuronal differentiation and animal models with which to evaluate physiological bioactivity associated with hESC derived neuronal populations.</gtr:partnerContribution><gtr:piContribution>Good Manufacturing Practice Grade Human pluripotent stem cell culture and qualification.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>DASC Stem Cell and Tissue Engineering Conference</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>E4637B7C-E4AF-48E8-926F-5941EE693F10</gtr:id><gtr:impact>Annual Danish Stem Cell Society Meeting</gtr:impact><gtr:outcomeId>57bb2177098990.69861842</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>https://dascs.nemtilmeld.dk/5/</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Edinburgh International Science Festival</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>7C2A8E0E-3922-413B-BC17-E8581CB75DEE</gtr:id><gtr:impact>Public lecture on opportunities and limitations of current state of the art in human pluripotent stem cell technology</gtr:impact><gtr:outcomeId>57bb2420a03062.08727789</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>BDEBATE</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>3F3FEC2C-544E-43A6-8817-1CF45511850D</gtr:id><gtr:impact>Professional discussion re: power and limitations of use of human cell technologies in discovery and therapy.</gtr:impact><gtr:outcomeId>57bb20159e3e61.11873707</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.bdebate.org/en</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>British Association for Tissue Banking</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>40D17032-C39B-4468-AC61-84B19FCEB337</gtr:id><gtr:impact>Reported on experience in standardised production of hPSC for clinical applications.</gtr:impact><gtr:outcomeId>57bb23b83a7aa0.61360942</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Toxbank Public Forum</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>0C5B71C8-08D2-434F-8C34-4E147835074C</gtr:id><gtr:impact>Lectured on own research underpinning use of hPSC in drug toxicity screening.</gtr:impact><gtr:outcomeId>57bb1f1b4ca722.72964718</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://toxbank.net/toxbank-public-forum</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Animal Cell Technology Industrial Platform</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>6D5BBDE1-9E9E-4BB2-89B7-DA13AB7C4A51</gtr:id><gtr:impact>Lecture to Pharmaceutical Company Scientists specializing in recombinant protein production on emerging opportunities arising from hPSC technology, generally and founded on our work.</gtr:impact><gtr:outcomeId>57bb2364998a37.78537366</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Industry/Business</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Oxford Stem Cell Symposium</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>B995FFBC-FA1B-48A3-9BAE-411FC116ABC4</gtr:id><gtr:impact>Presentation to peers covering our contributions to hPSC field.</gtr:impact><gtr:outcomeId>57bb22703663b6.86421676</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs><gtr:impactSummaryOutput><gtr:description>They have been used to inform the development of a device to separate/purify human stem and derivative cells.</gtr:description><gtr:firstYearOfImpact>2014</gtr:firstYearOfImpact><gtr:id>9B6E040A-D079-4FBD-93B5-5C3D1DCAB50A</gtr:id><gtr:impactTypes><gtr:impactType>Economic</gtr:impactType></gtr:impactTypes><gtr:outcomeId>54637b576b8891.73609038</gtr:outcomeId><gtr:sector>Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:impactSummaryOutput></gtr:impactSummaryOutputs><gtr:intellectualPropertyOutputs/><gtr:keyFindingsOutput><gtr:description>Industrial project management and development experience in support of commercial development of technology to separate human stem and derivative cells on the basis of their elasticity.</gtr:description><gtr:exploitationPathways>Device to positively or negatively purify stem and derivative cells being manufactured for industrial or therapeutic purposes.</gtr:exploitationPathways><gtr:id>D4E884F0-FEFE-4080-9113-CF44DB519056</gtr:id><gtr:outcomeId>54637afc1b6f89.87129962</gtr:outcomeId><gtr:sectors><gtr:sector>Healthcare,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:sectors></gtr:keyFindingsOutput><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>A means to scalably discriminate cells on the basis of variation in cell elasticity without recourse to cell labelling.</gtr:description><gtr:id>49EDE778-8150-4EEB-A6B7-08CA9CEB9365</gtr:id><gtr:impact>Label-free cell discrimination.</gtr:impact><gtr:outcomeId>57bb40632ca1e3.73698722</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>ELASTSEP</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>3FA56A9C-0925-4EA3-B7B6-7AC003B4DA05</gtr:id><gtr:title>Bioprocessing for Cell Based Therapies</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/330e2c4af264a3b2898eef86f9b65aff"><gtr:id>330e2c4af264a3b2898eef86f9b65aff</gtr:id><gtr:otherNames>Hoeve M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:outcomeId>5a93eaed4edd38.62193517</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3D0F1C76-0AE6-4B87-B704-849B9DB5D635</gtr:id><gtr:title>A scalable label-free approach to separate human pluripotent cells from differentiated derivatives.</gtr:title><gtr:parentPublicationTitle>Biomicrofluidics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e8eca9482f70c8fda1cbab9eb9c56529"><gtr:id>e8eca9482f70c8fda1cbab9eb9c56529</gtr:id><gtr:otherNames>Willoughby NA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1932-1058</gtr:issn><gtr:outcomeId>57bb012e0beb79.73354202</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ECBAE9FF-7D0A-4045-B551-74CE295CC80A</gtr:id><gtr:title>Challenges and advances in scale-up of label-free downstream processing for allogeneic cell therapies</gtr:title><gtr:parentPublicationTitle>Cell and Gene Therapy Insights</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f9e041217cc28728383e1f2a073f7200"><gtr:id>f9e041217cc28728383e1f2a073f7200</gtr:id><gtr:otherNames>Masri F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:outcomeId>5a93e9d1435900.77844961</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>91E32A1B-0BBB-44AF-98EF-7C83F9635CA6</gtr:id><gtr:title>Elasticity of human embryonic stem cells as determined by atomic force microscopy.</gtr:title><gtr:parentPublicationTitle>Journal of biomechanical engineering</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7584413ac3d007c7b3e8955553a36413"><gtr:id>7584413ac3d007c7b3e8955553a36413</gtr:id><gtr:otherNames>Kiss R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0148-0731</gtr:issn><gtr:outcomeId>pm_14981_21_22070334</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">BB/G010323/1</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>